TP53 and B-cell chronic lymphocytic leukemia: Notably, CLL patients with high-risk genetic alterations such as unmutated immunoglobulin heavy chain variant region (IGHV) status, TP53 aberrations and/or a complex karyotype derive major benefit with these novel agents compared to CIT [6, 7•].